Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Chemoprevention studies within lung cancer screening programmes

Published: 24 Nov 2015

Views: 1353

Rating:

Save

Dr Giulia Veronesi - Humanitas Research Hospital, Milan, Italy

Dr Veronesi discusses her article published in the Biomarkers, Screening and Prevention in Cancer special issue.

She explains the benefits of low dose CT screening, which individuals should undergo screening and whether the original screening trials turned out to be positive.

Read Dr Veronesi’s article here.

Related Videos

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Genomic testing: Awareness and effective communication between healthcare...

Prof Richard Simcock and Antonella Cardone

Genomic testing: Awareness and effective communication between healthcare professionals and patients ( Prof Richard Simcock and Antonella Cardone )

A biomarker led approach to bladder cancer

Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr...

A biomarker led approach to bladder cancer ( Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr Yohann Loriot )

Liquid biopsies and cancer: The role of NGS, CTC, exosomes, cfDNA and cfRNA

Dr Bruna Pellini - Moffitt Cancer Center, Tampa, USA

Liquid biopsies and cancer: The role of NGS, CTC, exosomes, cfDNA and cfRNA ( Dr Bruna Pellini - Moffitt Cancer Center, Tampa, USA )

Lung cancer screening and treatment in the Philippines

Dr Marcelo Severino Imasa - Lung Center of the Philippines, Manila, Philippines

Lung cancer screening and treatment in the Philippines ( Dr Marcelo Severino Imasa - Lung Center of the Philippines, Manila, Philippines )

Evidence-based approach to lymph node assessment and targeted axillary...

Prof Jessica Leung - MD Anderson Cancer Center, Houston, USA

Evidence-based approach to lymph node assessment and targeted axillary dissection ( Prof Jessica Leung - MD Anderson Cancer Center, Houston, USA )

Molecular profiling in prostate cancer: key challenges for clinical...

Dr Joaquin Mateo - Vall d’Hebron Institute of Oncology, Barcelona, Spain

Molecular profiling in prostate cancer: key challenges for clinical implementation ( Dr Joaquin Mateo - Vall d’Hebron Institute of Oncology, Barcelona, Spain )

EGFR mutations in NSCLC - from biomarker to treatment selections in second line

Prof Nicolas Girard, Prof Keith Kerr, Dr Joshua Reuss and Dr Alfredo Addeo

EGFR mutations in NSCLC - from biomarker to treatment selections in second line ( Prof Nicolas Girard, Prof Keith Kerr, Dr Joshua Reuss and Dr Alfredo Addeo )

ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer

Dr Neal Shore, Dr Pasquale Rescigno, Prof Noel Clarke and Dr Friederike...

ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer ( Dr Neal Shore, Dr Pasquale Rescigno, Prof Noel Clarke and Dr Friederike Schlürmann )

More from ecancer